Acadia Healthcare Co. (NASDAQ:ACHC) was the target of a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 10,835,580 shares, a growth of 11.5% from the August 15th total of 9,715,725 shares. Currently, 16.0% of the shares of the stock are short sold. Based on an average daily volume of 675,798 shares, the days-to-cover ratio is presently 16.0 days.

A number of equities research analysts have weighed in on ACHC shares. Royal Bank Of Canada cut their price target on shares of Acadia Healthcare from $86.00 to $78.00 and set an “outperform” rating for the company in a report on Monday, August 1st. Leerink Swann reissued a “buy” rating and issued a $80.00 price target on shares of Acadia Healthcare in a report on Sunday, August 28th. Jefferies Group reissued a “buy” rating and issued a $85.00 price target on shares of Acadia Healthcare in a report on Monday, June 27th. RBC Capital Markets reissued an “outperform” rating and issued a $78.00 price target (down from $86.00) on shares of Acadia Healthcare in a report on Monday, August 1st. Finally, Robert W. Baird cut their price target on shares of Acadia Healthcare from $67.00 to $66.00 and set an “outperform” rating for the company in a report on Thursday, September 15th. One analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the company. Acadia Healthcare has an average rating of “Buy” and an average target price of $78.46.

Shares of Acadia Healthcare (NASDAQ:ACHC) opened at 49.22 on Thursday. Acadia Healthcare has a 12 month low of $48.05 and a 12 month high of $75.11. The company has a market cap of $4.30 billion, a PE ratio of 26.29 and a beta of 0.84. The firm’s 50-day moving average price is $51.60 and its 200-day moving average price is $55.47.

Acadia Healthcare (NASDAQ:ACHC) last issued its earnings results on Friday, July 29th. The company reported $0.73 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.73. Acadia Healthcare had a return on equity of 9.35% and a net margin of 6.44%. The firm had revenue of $756.50 million for the quarter, compared to analysts’ expectations of $752.57 million. During the same quarter last year, the business earned $0.57 earnings per share. The company’s revenue was up 66.8% compared to the same quarter last year. Equities analysts predict that Acadia Healthcare will post $2.64 EPS for the current fiscal year.

In other Acadia Healthcare news, Director Reeve B. Waud sold 1,360,977 shares of the company’s stock in a transaction dated Friday, September 16th. The shares were sold at an average price of $48.52, for a total value of $66,034,604.04. Following the completion of the sale, the director now directly owns 55,673 shares of the company’s stock, valued at approximately $2,701,253.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO David M. Duckworth sold 16,670 shares of the company’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $54.33, for a total transaction of $905,681.10. Following the completion of the sale, the chief financial officer now directly owns 11,688 shares of the company’s stock, valued at $635,009.04. The disclosure for this sale can be found here. 17.20% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of ACHC. Royal Bank of Canada boosted its position in shares of Acadia Healthcare by 8.9% in the second quarter. Royal Bank of Canada now owns 61,510 shares of the company’s stock worth $3,407,000 after buying an additional 5,052 shares during the period. Calvert Investment Management Inc. boosted its position in shares of Acadia Healthcare by 0.9% in the second quarter. Calvert Investment Management Inc. now owns 4,192 shares of the company’s stock worth $232,000 after buying an additional 39 shares during the period. Schwab Charles Investment Management Inc. boosted its position in shares of Acadia Healthcare by 7.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 240,138 shares of the company’s stock worth $13,304,000 after buying an additional 16,989 shares during the period. Amalgamated Bank boosted its position in shares of Acadia Healthcare by 38.0% in the second quarter. Amalgamated Bank now owns 9,780 shares of the company’s stock worth $510,000 after buying an additional 2,691 shares during the period. Finally, Legal & General Group Plc boosted its position in shares of Acadia Healthcare by 6.0% in the second quarter. Legal & General Group Plc now owns 5,366 shares of the company’s stock worth $297,000 after buying an additional 302 shares during the period.

About Acadia Healthcare

Acadia Healthcare Company, Inc is a provider of behavioral healthcare services. The Company operates in two segments: U.S. Facilities and U.K. Facilities. The Company develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States, the United Kingdom and Puerto Rico.

5 Day Chart for NASDAQ:ACHC

Receive News & Ratings for Acadia Healthcare Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare Co. and related companies with MarketBeat.com's FREE daily email newsletter.